ArticleScientific reports2026
Wearable sensors for monitoring drug pharmacokinetics in patients with Parkinson's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wearable sweat sensors have attracted significant attention in recent years due to their potential for noninvasive health monitoring and point-of-care treatment. In this study, we developed and clinically evaluated wearable electrochemical sweat sensors in 32 patients with Parkinson’s disease (PD) at Taichung Veterans General Hospital, Taiwan. PD patients were treated with standard oral L-DOPA formulations, in terms of Madopar or Sinemet. PD symptoms were assessed using standard MDS-UPDRS scores, 10 clinical movement metrics, wearable inertial measurement units (IMUs) data, and sweat L-DOPA concentration profiles. Using these multimodal measurements, we found that 79% of PD patients with sufficient sweating showed a moderate to strong negative Spearman correlation (– 1.0 < ρ < – 0.4) between their sweat L-DOPA profiles and hand tremor intensity. These results highlight the potential of wearable sweat sensors for noninvasive monitoring of L-DOPA pharmacokinetics and enabling personalized dosage optimization in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.